Medtronic (MDT) FY2025 Earnings Quality Report

Grade: F — Cash Coverage and Goodwill Concentration

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2025-06-20) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP — Clean opinion (1 critical audit matter: income tax reserve for uncertain tax position related to Puerto Rico manufacturing)

**Fiscal Year**: Medtronic's fiscal year ends on the last Friday of April. FY2025 = April 27, 2024 through April 25, 2025.

One-line verdict: Medtronic's F grade comes from two mechanical fails — cash and short-term investments of $8.96B covers only 31% of $28.52B of total debt, and $53.41B of goodwill plus intangibles equals 111% of the $48.02B equity base. The underlying medical device business is steady: revenue grew 3.6% to $33.54B, net income rose 27% to $4.66B, FCF was $5.18B, CFFO/NI is 1.51, and the M-Score of -2.58 sits cleanly in the safe zone. Debt/EBITDA of 3.1x is manageable and gross margin held flat at 65.3%. The balance sheet structure is the cumulative legacy of the $49.9B Covidien acquisition (2015) and subsequent bolt-on M&A. This is a high-quality operating business with an M&A-heavy balance sheet, not an earnings manipulation story.

The Medical Device Leader with Four Segments

Medtronic operates four reportable segments, per the MD&A:

(Note: data pulled from the 10-K's half-year tables; segment totals summed across H1 and H2.)

From the MD&A: "The increase in net sales for fiscal year 2025 was driven by growth in most businesses, including strong growth in Cardiac Ablation Solutions, Cardiac Pacing Therapies, TAVR, Diabetes, Neuromodulation, Spine, and Advanced Energy. The net sales increase was partially offset by declines in Stapling and a $90 million incremental Italian payback accrual resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015."

GAAP to Non-GAAP Reconciliation

From the 10-K MD&A: "Fiscal year ended April 25, 2025 (in millions, except per share data) Income Before Income Taxes Income Tax Provision (Benefit) Net Income Attributable to Medtronic Diluted EPS Effective Tax Rate GAAP $ 5,628 $ 936 $ 4,662 $ 3.61 16.6 %"

Non-GAAP adjustments included:

Non-GAAP net income was $7,079M vs GAAP net income of $4,662M. The 34% gap between GAAP and non-GAAP numbers reflects the ongoing amortization of intangibles from prior acquisitions — primarily the $49.9B 2015 Covidien deal that added tens of billions in intangible assets that are still amortizing.

Operating income grew 18.5% on 3.6% revenue growth — strong operating leverage as restructuring charges in the prior year rolled off and gross margin held flat.

Cash Flow: Strong Conversion

CFFO of $7.04B against net income of $4.66B produces a 1.51x conversion ratio — clean for a medical device company. FCF of $5.18B supports the $3.60/share annual dividend (approximately $4.6B in total dividends) with room to spare.

The 18-Point Screening

Revenue Quality

All three revenue-quality checks pass. DSO is typical for medical devices (71 days), AR grew modestly faster than revenue but within normal variance, and CFFO growth matched revenue growth.

Expense Quality

Gross margin held essentially flat at 65.3% — impressive discipline given cost inflation, tariff exposure, and ongoing restructuring. CapEx grew 17% but the absolute dollars ($1.86B) are proportionate to a $33.5B revenue base.

Cash Flow Quality

C4 fail: Cash and short-term investments of $8.96B against total debt of $28.52B = 31% coverage. Debt/EBITDA of 3.1x is healthy and FCF of $5.18B comfortably services the debt, but the mechanical ratio fails the screen.

Balance Sheet

D1 fail: Goodwill of $41.74B plus other intangibles of $11.67B = $53.41B, or 111% of the $48.02B equity base. The goodwill alone ($41.74B) represents the accumulated M&A of decades — primarily the 2015 Covidien deal. Intangibles declined from $13.22B to $11.67B ($-1.55B) as acquired technology amortized per the non-GAAP amortization disclosure. Goodwill itself grew modestly from $40.99B to $41.74B.

M&A Risk

Goodwill+intangibles declined 1% YoY — amortization exceeded new acquisition activity. This is a declining-ratio trajectory, slowly improving the balance sheet structure over time.

Beneish M-Score

Key Risks from Item 1A

1. Competition in a rapidly evolving medical device market. From the 10-K: "We operate in a highly competitive industry and we may be unable to compete effectively. We compete in both the therapeutic and diagnostic medical markets in more than 150 countries throughout the world. These markets are characterized by rapid change resulting from technological advances, innovations and scientific discoveries. In the product lines in which we compete, we face a range of competitors from large companies with multiple business lines to small, specialized manufacturers that offer a limited selection of niche products. Development by other companies of new or improved products, processes, technologies, or the introduction of reprocessed products or generic versions when our proprietary products lose their patent protection may make our existing or planned products less competitive. In addition, we face competition from providers of alternative medical therapies, such as pharmaceutical companies, including those producing GLP-1s."

The GLP-1 callout is noteworthy: Medtronic is explicitly flagging the Ozempic/Wegovy class as a competitive pressure on metabolic disease device markets (particularly Diabetes segment).

2. Managed care and pricing pressure. "In the current environment of managed care, consolidation among healthcare providers, increased competition, declining reimbursement rates, and national and provincial tender pricing, as recently experienced in China, competitively priced product offerings are essential to our success." The China tender pricing callout is specific and ongoing.

3. AI and emerging technology compliance. "For example, data science, machine learning and AI are all impacting our products and operations and the competitive landscape in which we operate, and the application of these technologies is rapidly evolving at the same time as new laws and regulations of AI are being developed in jurisdictions around the world. Compliance with developing regulations may require significant expenditures or may limit our ability to effectively use these technologies."

4. Supply chain and manufacturing interruption. "Reduction or interruption in supply or other manufacturing difficulties may adversely affect our manufacturing operations and related product sales. The manufacture of our products requires the timely delivery of a sufficient amount of quality components and materials and is highly exacting and complex, due in part to complex trade and strict regulatory requirements."

5. European Union Medical Device Regulations (EU MDR). The non-GAAP adjustment table includes "Medical device regulations (5) 52" for FY2025 — ongoing compliance costs from the EU MDR regime that add recurring expenses beyond what the company considers underlying operational costs.

6. Italian payback accruals. A direct earnings impact disclosed in the 10-K: "(6) Reflects the recognition of incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015." These added $90M to the FY2025 revenue line as a negative adjustment.

7. Puerto Rico manufacturing uncertain tax position (the sole critical audit matter). From PwC: "A remaining unresolved issue with the IRS relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's manufacturing sites. These reserves are subject to a high degree of estimation and management judgment. Total reserves relating to uncertain tax positions as of April 25, 2025 were $2.902 billion, of which the Puerto Rico manufacturing reserve makes up a significant portion."

The $2.9B in uncertain tax positions is one of the largest estimates on Medtronic's balance sheet. PwC specifically calls out the need to evaluate consistency with the U.S. Tax Court ruling that affects the dispute. Any adverse final outcome would flow directly through the income statement as additional tax expense.

Altman Z-Score and F-Score

Z-Score of 3.53 is comfortably in the safe zone despite the high goodwill-to-equity ratio — the strong EBITDA and low current liabilities offset the intangible asset heaviness in the model.

Summary

Grade: F. Fifteen passing checks with two mechanical fails on cash coverage and goodwill intensity — the direct legacy of historic M&A.

Medtronic runs a high-quality medical device operation with clean revenue quality, expense discipline, and cash conversion. Revenue grew 3.6%, operating income grew 18.5%, CFFO was $7.04B, FCF was $5.18B, gross margin held flat at 65.3%, and the M-Score of -2.58 shows no manipulation signals. Operating leverage improved meaningfully in FY2025 as restructuring charges faded.

The F grade reflects the balance sheet structure inherited from years of M&A:

The most meaningful single risk is the $2.9B uncertain tax position related to the Puerto Rico manufacturing arrangement — PwC's sole critical audit matter and a reserve that awaits resolution of the related U.S. Tax Court case. The operating risks (GLP-1 competition, China tender pricing, EU MDR compliance, Italian payback accruals) are ongoing headwinds but each is individually modest.

Medtronic's financial health is structurally good; the F grade is an artifact of how the Covidien-era balance sheet interacts with the engine's mechanical thresholds, not a warning about current earnings or operations.

**Disclaimer**: This report is based on Medtronic's FY2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.

Data: SEC EDGAR 10-K (Filed 2025-06-20) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP (Unqualified opinion, 1 critical audit matter)